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Abstract
Background Obesity is a risk for many different cancers. Laparoscopic sleeve gastrectomy (LSG) is common, and benign or pre-
malignant histopathology types are reported in the removed gastric specimens. We assessed whether higher BMI was associated
with certain benign or pre-malignant histopathological changes.
Method Retrospective chart review of all primary LSG patients (N= 1555). Demographic, clinical, and LSG histopathology data were
retrieved. BMI of patients with specific benign or pre-malignant conditions in their gastric specimens was compared with the BMI of the
rest of the patients with abnormal histopathology specimens and also compared with the BMI of patients with normal control specimens.
Results Females comprised 70% of the patients. Mean BMI were 46.3 (females) and 48 (males). Normal LSG specimens
comprised 52%. Most common abnormal histopathologies were chronic inactive gastritis (33%), chronic active gastritis
(6.8%), follicular gastritis (2.7%), lymphoid aggregates (2.2%), intestinal metaplasia (1.4%) and GIST (0.7%). After controlling
for confounders (age, gender,H. pylori, diabetes mellitus type 2, hypertension), no significant association was observed between
the BMI of patients with specific benign or pre-malignant histopathology compared with the BMI of the rest of the patients with
abnormal histopathologies and compared to the BMI of patients with normal histopathologies.
Conclusion When confounders were taken into account, there appeared no significant associations between the BMI of patients
with specific benign or pre-malignant histopathology compared with the BMI of the rest of the patients with abnormal histopa-
thologies and compared to the BMI of patients with normal histopathologies of their gastric specimens. There was a very weak
correlation between BMI and other covariates.
Keywords Laparoscopic sleeve gastrectomy . LSG . Histopathologies . BMI . Pre-malignant histopathology . Benign
histopathology
Introduction
Bariatric procedures are common worldwide as a result of the
obesity epidemic [1, 2], and laparoscopic sleeve gastrectomy
(LSG) is a widely practised procedure. Obese patients are at a
higher risk of many cancers, e.g. endometrial and gastric can-
cer, oesophageal adenocarcinoma, as well as liver, kidney, and
colorectal cancers [3–10]. LSG histopathology specimens
may contain pre-malignant conditions such as follicular gas-
tritis, lymphoid aggregate, intestinal metaplasia, gastrointesti-
nal stromal tumour (GIST), atrophic chronic gastritis, autoim-
mune gastritis and dysplastic neuroendocrine nodule [10–16].
However, despite that obese patients are at higher risk ofmany
cancers and despite the increased risk of pre-malignant condi-
tions in LSG histopathology specimens, the literature suggests
that very sparse research has been undertaken to explore the
associations between BMI and histopathological changes
identified in the gastric specimens of LSG patients [10,
17–19]. It is important to scrutinise the relationship between
BMI and different histopathologies in morbidly obese patients
undergoing LSG in order to assess whether higher BMI
* Walid El Ansari
welansari9@gmail.com
1 Department of Bariatric Surgery, Hamad General Hospital, Hamad
Medical Corporation, Doha, Qatar
2 Department of Surgery, Hamad General Hospital, Hamad Medical
Corporation, PO Box 3050, Doha, Qatar
3 College of Medicine, Qatar University, Doha, Qatar
4 School of Health and Education, University of Skövde,
Skövde, Sweden
5 Weill Cornell Medicine, Doha, Qatar
Obesity Surgery (2019) 29:2166–2173
https://doi.org/10.1007/s11695-019-03801-y
# The Author(s) 2019
patients may be associated with higher rate of pre-malignant
histopathologies and thus, the possibility that patients with
higher BMI may need additional pre-operative workup.
Therefore, the aim of the current study was to examine,
among LSG patients, the relationship between BMI and dif-
ferent histopathologies identified in the removed gastric spec-
imens. The study sought to answer five specific questions:
1. Is the BMI of patients with given abnormal specimens
(whether benign or pre-malignant) different from the
BMI of controls with all abnormal specimens other than
the given one?;
2. Is the BMI of patients with abnormal specimens (whether
benign or pre-malignant) different from the BMI of con-
trols with normal specimens?;
3. Is the BMI of patients with pre-malignant specimens dif-
ferent from the BMI of controls with normal specimens?;
4. Is the BMI of patients with benign specimens different
from the BMI of controls with normal specimens?; and
5. Is the BMI of patients with benign specimens different
from the BMI of controls with abnormal pre-malignant
specimens?
Table 1 depicts the five research questions that the study
sought to answer, along with the cases and controls employed
for each question.
Materials and Methods
Ethics and Sample
The Medical Research Center at Hamad Medical Corporation
approved the study protocol (Proposal No. 16202/16). The
study was undertaken at Hamad General Hospital (HGH),
the largest hospital in Qatar. We retrospectively analysed the
demographic, clinical, and histopathologic data of patients
who had undergone primary LSG at HGH from February
2011 to July 2014 (n = 1555).
Procedures and Data Collection
During this period, every LSG patient had pre-operative
esophagogastroduodenoscopy routinely, in accordance with
EAES guidelines and CLO test routinely, to detect
Helicobacter pylori (H. pylori), where positive patients were
given the standard triple therapy: amoxicillin and
clarithromycin (2 weeks) and proton pump inhibitor
(2 months). Our histopathology department examined all gas-
tric LSG specimens macro- and microscopically and specified
a diagnosis. Clinical data [age, gender,H. pylori, hypertension
(HTN), type 2 diabetes (DM2)] and the findings of the histo-
pathology specimens were extracted from the electronic med-
ical records. The abnormal histopathologies were categorised
into benign and pre-malignant histopathologies.
Statistical Analysis
Statistical analyses were done using statistical packages SPSS
22.0 (SPSS Inc. Chicago, IL) and Epi Info 2000 (Centers for
Disease Control and Prevention, Atlanta, GA). A two-sided p
value < 0.05 was considered statistically significant.
Descriptive statistics summarised all demographic, anthropo-
metric, clinical and other related characteristics of the partici-
pants. Normally distributed data and results were reported as
mean and standard deviation (SD); the remaining results were
reported with as median and interquartile range (IQR).
Categorical data were summarised using frequencies and per-
centages. The primary outcome variable was to assess the
relationship between BMI and different benign and pre-
malignant histopathologies. Chi-square (χ2) test and/or
Fisher Exact test as appropriate assessed associations between
two or more qualitative variables (such as gender, co-
morbidities etc. with BMI). Unpaired ‘t’ or Mann Whitney
U test as appropriate assessed quantitative data between the
two independent groups. The relationship between BMI and
other variables (age, gender, H. pylori, HTN, DM2 and differ-
ent histopathologies) were assessed using Pearson’s/
Spearman’s correlation coefficients. Further, we applied linear
Table 1 Research questions, cases and controls
1. Is the BMI of patients with given abnormal specimens different from the BMI of controls with all abnormal specimens other than the given one?
Cases: Individual type of abnormal specimens Controls: All abnormal specimens other than given one
2. Is the BMI of patients with abnormal specimens different from the BMI of controls with normal specimens?
Cases: Individual type of abnormal specimens Controls: All normal histopathology specimens
3. Is the BMI of patients with abnormal pre-malignant specimens different from the BMI of controls with normal specimens?
Cases: All abnormal pre-malignant specimens combined Controls: All normal histopathology specimens
4. Is the BMI of patients with abnormal benign specimens different from the BMI of controls with normal specimens?
Cases: All abnormal benign specimens combined Controls: All normal histopathology specimens
5. Is the BMI of patients with abnormal benign specimens different from the BMI of controls with abnormal pre-malignant specimens?
Cases: All abnormal benign specimens combined Controls: All abnormal pre-malignant specimens combined
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regression methods to assess the relationship between BMI
and all independent covariates stated above, and we estimated
the regression coefficient from the linear regression model
considering BMI as the outcome variable of interest.
Results
Table 2 shows the demographic, anthropometric and clinical
characteristics of LSG patients (N = 1555). About 70% of the
sample were females. Mean BMI and age for females and
males were 46.3 and 48 years, and 36 and 35.3 years, respec-
tively. H. pylori, HTN and DM2 were present in 39.9%,
40.2% and 21% and 16.7% and 21.7%, 10.1%, of males and
females, respectively.
Table 3 depicts the histopathology characteristics of the
LSG specimens. A total of 52% of the histopathology sample
were normal. The most common abnormal histopathologies
were chronic inactive gastritis (33%), chronic active gastritis
(6.8%), follicular gastritis (2.7%), lymphoid aggregates
(2.2%), intestinal metaplasia (1.4%) and GIST (0.7%). Rare
histopathologies also existed, each comprising less than 0.2%.
We categorised the abnormal histopathologies into benign and
pre-malignant conditions. Benign lesions included chronic in-
active gastritis, chronic active gastritis and others (fundic
gland polyp, lymphoplasmacytic non-caseating granuloma,
submucosal fibrosis with eosinophil-rich chronic inflamma-
tion, focal gangrenous necrosis, mesothelial chronic inflam-
mation, focal prominence of intramural neural tissue, pancre-
atic heterotopia, leiomyoma and gastric lipoma). Pre-
malignant lesions included follicular gastritis, lymphoid ag-
gregate, intestinal metaplasia, GIST and others (atrophic
chronic gastritis, autoimmune gastritis, dysplastic neuroendo-
crine nodule).
Table 4 shows the comparisons between the different be-
nign and pre-malignant histopathologies with each other and
with normal controls. In terms of BMI, for each of the five
research questions that were examined, no significant associ-
ations were observed between the different types of histopa-
thologies and the different control specimens.
Spearman correlation showed very weak correlations be-
tween BMI and the other covariates (age, gender, H. pylori,
HTN, DM2, where correlation values ranged between 0.002–
0.077). Exploratory linear regression analysis was undertaken
to assess the predictive strength of BMI using the covariates.
R2 (coefficient of determination) value was less than 0.05 in
most of the cases (data not presented).
Discussion
There exists a noticeable deficiency in the published literature
that examined the relationships between different histopathol-
ogies of LSG specimens and BMI. In the current study, the
BMI of patients with either benign or pre-malignant histopa-
thologies in the LSG specimens was not significantly different
when compared with the BMI of patients having other histo-
pathologies or with BMI of controls with normal specimens
(Table 4). Likewise, the BMI of patients with benign speci-
mens (grouped together) was not significantly different than
the BMI of controls with normal specimens. Similarly, the
BMI of patients with pre-malignant specimens (grouped to-
gether) was not significantly different from the BMI of con-
trols with normal specimens. In addition, the BMI of patients
with benign lesions was not significantly different than the
BMI of patients with pre-malignant lesions.
One study of five GIST cases reported significantly lower
BMI for patients with GIST compared to patients without
GIST histopathology [17]. In contrast, a study in USA found
no significant difference between LSG specimens with abnor-
mal pathology (i.e. not containing H. pylori or gastric meta-
plasia) vs. specimens with significant pathology (i.e. contain-
ing H. pylori or gastric metaplasia) [18]. Likewise, others
reported no significant relationship between BMI and the
presence or absence of gastric atrophy, H. pylori, lymphoid
follicle and lymphoid aggregates [19]. An exception was in-
testinal metaplasia, which was associated with lower BMI
(40.8) when compared to other abnormal specimens (atrophy,
H. pylori, lymphoid follicle and lymphoid aggregate) that did
not have intestinal metaplasia (BMI 44.9, p < 0.0001) [19].
However, the current study observed that patients with
GIST, intestinal metaplasia or lymphoid aggregates had gen-
erally higher BMI compared to patients without these partic-
ular conditions or compared to patients with normal histopa-
thology, but the differences were not statistically significant.
Table 2 Demographic, anthropometric and clinical characteristics of
LSG patients (N = 1555)
Characteristic Male Female
N = 471 (30.3%) N = 1084 (69.7%)
Age (years)
M ± SD 35.3 ± 11.4 36 ± 10.3
Range 13–74 14–65
BMI
M± SD 48 ± 9.1 46.3 ± 8.1
Range 25–72 20–74
H. pylori
Yes (%) 39.9 40.2
Hypertension
Yes (%) 21.0 16.7
Diabetes mellitus
Yes (%) 21.7 10.1
M mean, SD standard deviation
2168 OBES SURG (2019) 29:2166–2173
Likewise, in the current study, patients with follicular gastritis
generally exhibited higher BMI than patients without such
pathology or compared to patients with normal LSG speci-
mens (BMI of follicular gastritis patients 48.3 vs. other histo-
pathology 46.6 vs. normal 46.5), but again, and differences
were not statistically significant (Table 4).
Such inconsistent findings across the various studies raise
four interlacing issues: categorisation of groups of histopa-
thology types, sample size, confounding and controls.
In terms of categorisation of groups of histopathology
types, studies are inconsistent in the ways they categorise
groups of histopathologies. Such undertaking renders the
comparisons of the findings of different studies difficult and
probably imprecise. For instance, one study categorised the
histopathologies they found into LSG specimens with abnor-
mal pathology (i.e. not containing H. pylori or gastric meta-
plasia) vs. specimen with significant pathology (containing
H. pylori or gastric metaplasia) [18]. Whilst it is not clear
why H. pylori (an infection) was classified as pathology, the
result is that comparisons between studies may consequently
lack precision. In contrast to Hansen et al. [18], the current
study observed that H. pylori is a potential confounder rather
than pathology and employed it as such in the analysis (de-
tailed below). Future research would benefit from a
standardisation of the ways employed to categorise groups
of histopathologies for more meaningful comparisons.
As for the sample size, among the sparse literature that
assessed the relation between the BMI and histopathology of
LSG specimens, the current study’s sample size was the larg-
est (1555 patients) when compared to others, e.g. Adalı et al.
(37 patients with pathology) [19], Hansen et al. (351 patients,
but not entirely clear if all were with pathology) [18] or Yuval
et al. (827 patients, 5 GIST patients vs. 822 control group not
having GIST pathology) [17]. Such large sample size provid-
ed the current study the advantage of minimizing the chance
of assuming a false premise as true [20].
In connection with confounding variables, the current
study is unique in that it controlled for potential confounding
variables (e.g. age, gender, H. pylori infection, DM, HTN)
when examining the relationship between different histopa-
thologies of LSG specimens and BMI. Most previous studies
had not undertaken such controlled analysis. For instance,
Table 3 Characteristics of LSG
histopathology specimens (N =
1555)
Histopathology of LSG Specimen n (%)
Normal histopathology 810 (52)
Abnormal histopathology 745(48)
Chronic inactive gastritis (mild or moderate) 512 (33)
Chronic active gastritis 105 (6.8)
Follicular gastritis 43 (2.7)
Lymphoid aggregate 35 (2.2)
Intestinal metaplasia 22(1.4)
GIST 11(0.7)
Fundic gland polyp 3 (0.19)
Atrophic chronic gastritis 3 (0.19)
Lymphoplasmacytic non-caseating granuloma 2 (0.13)
Submucosal fibrosis with eosinophil-rich chronic inflammation 1 (0.06)
Focal gangrenous necrosis 1 (0.06)
Autoimmune gastritis 1 (0.06)
Mesothelial chronic inflammation 1 (0.06)
Focal prominence of intramural neural tissue 1 (0.06)
Dysplastic neuroendocrine nodule 1 (0.06)
Leiomyoma 1 (0.06)
Pancreatic heterotopia 1 (0.06)
Gastric lipoma 1 (0.06)
All benigna 629 (40.5)
All pre-malignantb 116 (7.5)
LSG laparoscopic sleeve gastrectomy, GIST gastrointestinal stromal tumour. a includes chronic inactive gastritis,
chronic active gastritis and others (fundic gland polyp, lymphoplasmacytic non-caseating granuloma, submucosal
fibrosis with eosinophil-rich chronic inflammation, focal gangrenous necrosis, mesothelial chronic inflammation,
focal prominence of intramural neural tissue, pancreatic heterotopia, leiomyoma and gastric lipoma; b includes
follicular gastritis, lymphoid aggregate, intestinal metaplasia, GIST and others (atrophic chronic gastritis, auto-
immune gastritis, dysplastic neuroendocrine nodule)
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with the exception of Hansen et al. [18] who controlled for
gender, medical comorbidities and H. pylori (but not age) in
their analysis, previous studies do not seem to have controlled
for any confounding variables that could have influenced their
findings. Yuval et al. [17] did not control for age, gender,
diabetes mellitus and HTN in their examination of the BMI
of patients with GIST histopathology vs. the BMI of patients
with noGIST histopathology; Saafan et al. [10] did not control
for age, gender and H. pylori, and Adalı et al. [19] did not
control for age, gender and diabetes mellitus in their assess-
ment of the BMI of patients with different histopathologies
(gastritis, atrophy, H. pylori, intestinal metaplasia, lymphoid
follicle and lymphoid aggregate). Confounding is a distortion
(inaccuracy) in the estimated measure of association that oc-
curs when the primary exposure of interest is mixed up with
some other factor that is associated with the outcome [21].
Hence, such controlling for a range of important confounding
variables as the current study undertook e.g. age, gender,
H. pylori, DM and HTN is critical in order to assess the ‘true’
relationship between LSG histopathology and BMI.
As confounding is a situation in which the association be-
tween an exposure and outcome is distorted by the presence of
another variable [22], confounders raise two critical points.
The first is that research of the relationships between histopa-
thologies of LSG specimens and BMI, e.g. [10, 17, 19] all did
not control for age, gender and diabetes mellitus in their as-
sessment of the BMI of patients of different histopathologies,
despite that these studies, judging from our appraisal of these
studies’ findings, seem to have had the data necessary for such
controlled analyses available. This suggests that bariatric
researchers will need to have heightened awareness of poten-
tial confounders, to collect the necessary data, and more im-
portantly, include it in the analyses as mandatory.
The second point is that, given that confounders are
variables that have a relationship to the exposure [23]
(in this case, possibly BMI) and are also independently
associated with the outcome (abnormal LSG histopathol-
ogy), it is critical that a suspected confounder’s relation-
ships with both exposure and outcome are first
ascertained for the relationship under examination. We
ascertained such relationships in the context of the asso-
ciations that the current study examined. In terms of their
independent association with the outcome (abnormal his-
topathology), older age was significantly associated with
GIST and intestinal metaplasia [10, 24, 25]; females were
significantly associated with chronic active gastritis [10];
there is evidence that H. pylori is significantly associated
with each of follicular gastritis, lymphoid aggregates, gas-
tritis and intestinal metaplasia [10, 25–27] and with GIST
[10]; and diabetes mellitus was associated with gastritis
[28]. Nevertheless, to the best of our knowledge, there is
still no evidence of a significant association between hy-
pertension and LSG histopathology. As for a potential
confounder’s association to the exposure under examina-
tion, BMI was significantly associated with HTN [29],
DM2 [30], H. pylori [31], gender [32] and age [32]. The
current study used multivariable regression analysis to
control for such identified confounders during data anal-
ysis, as recommended by others [33]. The current study
also acknowledges that as the number of confounders that
Table 4 Comparisons between BMI of cases vs. different controls
Controls (all other histopathologies) Pa Controls (normal) Pb
Histopathology N BMI N BMI N BMI
Benign lesions
Chronic inactive gastritis 512 46.8 ± 8.2 233 46.2 ± 7.9 1.000 810 46.5 ± 8.0 1.000
Chronic active gastritis 105 47.7 ± 7.6 640 46.4 ± 8.2 0.301 810 46.5 ± 8.0 0.372
Others benign 12 41.8 ± 10.5 733 46.8 ± 8.5 0.811 810 46.5 ± 8.0 0.770
Pre-malignant lesions
Follicular gastritis 43 48.3 ± 10.9 703 46.6 ± 8.1 1.000 810 46.5 ± 8.0 1.000
Lymphoid aggregate 35 44.8 ± 7.2 710 46.7 ± 8.1 0.463 810 46.5 ± 8.0 0.583
Intestinal metaplasia 22 44.5 ± 8.6 723 46.6 ± 8.1 0.688 810 46.5 ± 8.0 0.791
GIST 11 43.2 ± 8.1 734 46.6 ± 8.1 0.510 810 46.5 ± 8.0 0.564
Others pre-malignant 5 44.4 ± 6.7 740 46.8 ± 8.6 0.615 810 46.5 ± 8.0 0.637
All benign vs. all pre-malignant 629c 47.0 ± 8.4 116 d 45.7 ± 9.0 0.924 – – –
All benign vs. all normal 629c 47.0 ± 8.4 – – – 810 46.5 ± 8.0 0.702
All pre-malignant vs. all normal 116d 45.7 ± 9.0 – – – 810 46.5 ± 8.0 0.918
Analysis controlled for age, gender, H. pylori infection, diabetes mellitus and hypertension; all BMI values expressed as mean ± standard deviation;
a denotes the p value of differences in the BMI of patients with specific abnormal specimens vs. controls with abnormal LSG specimens other than the
given one; b denotes the p value of differences in the BMI of patients with abnormal LSG specimens vs. controls with normal specimens; c includes all
benign abnormal specimens; d includes all pre-malignant abnormal specimens; an en dash denotes not applicable
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can be controlled for simultaneously is limited (may lead
to small numbers in some strata), regression is frequently
employed to control for more than one confounder at the
same time [23].
Finally, in terms of controls, few studies have emphasised
the importance of the appropriate selection of control groups
[34]. The question ‘Compared toWhat?’ is critical when com-
parator group/s are employed, and there has been calls regard-
ing the consideration of appropriate comparator group/s in the
context of the relationships between different LSG histopa-
thologies and BMI [35]. The use of a comparative group is
essential for valid study findings, and the choice of ‘which
comparator?’ could influence the internal validity of a study.
Others have noted the research that included a control group
did not state the explicit principles employed in the selection
of controls, e.g. how controls were selected and why specific
controls were engaged, suggesting a lack of scientific ap-
proach in the choice of controls [34]. For instance, one study
[19] compared between specific abnormal histopathology and
all other histopathologies as control but did not seem to ex-
plicitly state why such controls (and not normal controls) were
used. Often, controls might comprise an easily obtained con-
venience group that might not necessarily be in agreement
with the principles of control selection, resulting in selection
bias [34]. Hence, the current study made explicit the selection
of a series of different controls appropriate to answer each of
the five questions that the study examined (Table 1). The
answer to all these five questions was that there were no sig-
nificant differences in BMI between the groups when age,
gender, H. pylori infection, DM and HTN were controlled
for in Spearman’s correlation and multivariable analysis.
Generally, pre-malignant lesions identified in LSG
specimens across 11 studies varied from 4.1 to 33.2%
[10, 18, 36–44]. However, across these 11 above-
mentioned studies, there was zero actual malignancy
reported, despite that these studies were undertaken in
a wide variety of geographical areas worldwide with
different risk of gastric cancers. The lack of any malig-
nancy in LSG specimens across these studies is in
agreement with the findings of the current research. In
addition, the literature on LSG specimens is certainly
sparse on information about the definite risk of pre-
malignant gastric lesions that actually turn malignant.
Thus, even with our 7.5% pre-malignant lesions identi-
fied in LSG specimens, and with the huge number of
LSG procedures undertaken worldwide, such current
lack of the evidence base renders us unable to extrapo-
late in any way the potential number of patients with
pre-malignant lesions that would actually turn malignant
or whether such numbers would be high and alarming
or otherwise. Hence, there exists much debate regarding
the role of routine histopathological examination of LSG
specimens [10, 18, 36–44], and some authors have
suggested that histopathological examination of LSG
specimens is to be done when intraoperative macroscop-
ic pathology is observed [10, 18, 43]. Future research
would benefit from addressing these points.
This study has limitations. It is a retrospective study
with its inherent limitations (e.g. potentially missing pa-
tients). Some of the pathologies had only a few or one
case (e.g. gastric lipoma, leiomyoma, autoimmune gas-
tritis) (Table 2), rendering comparisons not very reliable.
The relationship between BMI and histopathology is not
a causation but rather, is an association as it cannot be
determined if exposure (BMI) preceded disease (histopa-
thology). Patients with no H. pylori detected at pre-
operative OGD were not tested to assess if they had
previous H. pylori infection that was eradicated but
could have contributed to the current histopathology
identified. Future research should try to overcome such
limitations, particularly with employing larger number
of patients with each abnormal histopathology in order
to confirm or refute the findings of the current study.
Conclusion
In the current study, among the 1555 patients who had
LSG, after controlling for confounding variables (age,
gender, H. pylori, diabetes mellitus type 2, hyperten-
sion), there was no significant association between
BMI and either the different benign or pre-malignant
histopathologies identified in their gastric specimens.
Moreover, there was a very weak correlation between
BMI and the other covariates (age, gender, H. pylori,
HTN, DM2).
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